These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype. Yoshimura M; Sakamoto M; Ikemoto M; Mochizuki Y; Yuasa K; Miyagoe-Suzuki Y; Takeda S Mol Ther; 2004 Nov; 10(5):821-8. PubMed ID: 15509500 [TBL] [Abstract][Full Text] [Related]
10. [Gene therapy for muscular dystrophy]. Takeda S No To Hattatsu; 2004 Mar; 36(2):117-23. PubMed ID: 15031985 [TBL] [Abstract][Full Text] [Related]
11. Antisense pre-treatment increases gene therapy efficacy in dystrophic muscles. Peccate C; Mollard A; Le Hir M; Julien L; McClorey G; Jarmin S; Le Heron A; Dickson G; Benkhelifa-Ziyyat S; Piétri-Rouxel F; Wood MJ; Voit T; Lorain S Hum Mol Genet; 2016 Aug; 25(16):3555-3563. PubMed ID: 27378686 [TBL] [Abstract][Full Text] [Related]
12. Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice. Bostick B; Yue Y; Lai Y; Long C; Li D; Duan D Hum Gene Ther; 2008 Aug; 19(8):851-6. PubMed ID: 18666839 [TBL] [Abstract][Full Text] [Related]
13. Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models. Song Y; Morales L; Malik AS; Mead AF; Greer CD; Mitchell MA; Petrov MT; Su LT; Choi ME; Rosenblum ST; Lu X; VanBelzen DJ; Krishnankutty RK; Balzer FJ; Loro E; French R; Propert KJ; Zhou S; Kozyak BW; Nghiem PP; Khurana TS; Kornegay JN; Stedman HH Nat Med; 2019 Oct; 25(10):1505-1511. PubMed ID: 31591596 [TBL] [Abstract][Full Text] [Related]
14. Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products. Yuasa K; Yoshimura M; Urasawa N; Ohshima S; Howell JM; Nakamura A; Hijikata T; Miyagoe-Suzuki Y; Takeda S Gene Ther; 2007 Sep; 14(17):1249-60. PubMed ID: 17581597 [TBL] [Abstract][Full Text] [Related]
15. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Wang Z; Kuhr CS; Allen JM; Blankinship M; Gregorevic P; Chamberlain JS; Tapscott SJ; Storb R Mol Ther; 2007 Jun; 15(6):1160-6. PubMed ID: 17426713 [TBL] [Abstract][Full Text] [Related]
16. Combined effect of AAV-U7-induced dystrophin exon skipping and soluble activin Type IIB receptor in mdx mice. Hoogaars WM; Mouisel E; Pasternack A; Hulmi JJ; Relizani K; Schuelke M; Schirwis E; Garcia L; Ritvos O; Ferry A; 't Hoen PA; Amthor H Hum Gene Ther; 2012 Dec; 23(12):1269-79. PubMed ID: 22894762 [TBL] [Abstract][Full Text] [Related]
17. The Effect of Immunomodulatory Treatments on Anti-Dystrophin Immune Response After AAV Gene Therapy in Dystrophin Deficient mdx Mice. Li N; Parkes JE; Spathis R; Morales M; Mcdonald J; Kendra RM; Ott EM; Brown KJ; Lawlor MW; Nagaraju K J Neuromuscul Dis; 2021; 8(s2):S325-S340. PubMed ID: 34569971 [TBL] [Abstract][Full Text] [Related]